Clinical Trial Update: A Study Assessing the Safety and Efficacy of Multiple Intravitreal KH902 in Patients With CNV Due to AMD [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the safety and efficacy of KH902 injected intravitreally for neovascular age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• KH902

Snippet

Sponsor: Chengdu Kanghong Biotech Co., Ltd. | Conditions: Neovascular Age-related Macular Degeneration | Phase 1, Phase 2 | Status: COMPLETED